Article

Costing ‘the’ MTD

2017-06-16

Abstract excerpt

<h4>Background:</h4> Absent adaptive, individualized dose-finding in early-phase oncology trials, subsequent registration trials risk suboptimal dosing that compromises statistical power and lowers the probability of technical success (PTS) for the investigational drug. While much methodological progress has been made toward adaptive dose-finding, and quantitative modeling of dose-response relationships, most suc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2a8e5a4c-8d2e-5f9e-8232-3e0cef06c955
DOI: 10.1101/150821

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Costing ‘the’ MTDDOI 10.1101/150821Read

Costing ‘the’ MTD … in 2-DSemantic proximity Read

Envelope Simulation: A New Adaptive Method for Dose OptimizationSemantic proximity Read

Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor DynamicsSemantic proximity Read

CFO: Calibration-Free Odds Bayesian Designs for Dose Finding in Clinical TrialsSemantic proximity Read

Should the choice of BOIN design parameter<i>p.tox</i>only depend on the target DLT rate?Semantic proximity Read

Should the Choice of BOIN Design Parameter <em>p.tox</em> only Depend on the Target DLT Rate?Semantic proximity Read

Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.Semantic proximity Read

Sequential designs for individualized dosing in phase I cancer clinical trials.Semantic proximity Read

The Generalized 3+3 (G3+3) Design for Phase I Dose-Finding TrialsSemantic proximity Read

Adaptive designs for complex dose finding studiesSemantic proximity Read

Predicting Treatment Outcomes from Adaptive Therapy — A New Mathematical BiomarkerSemantic proximity Read

Radiation therapy with phenotypic medicine: towards N-of-1 personalization.Semantic proximity Read